LPV 100mg / r 25mg, tab.

NST DORALPVR4T-

Outdated Article

Former Code(s): -X DORALPRF1T2 DORAZBD0481 DORAZBD0482 DORAZFR0511 DORAZYN1057

Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AR10
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.

OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

https://msf.oodin.sh/web/image/product.template/572453/image_1920?unique=6a98e8c

This combination does not exist.

Add article to list

   

Add Kit To Wishlist

   

LOPINAVIR (LPV) / RITONAVIR (r)

Therapeutic Action

Fixed-dose combination (FDC) of two antiretrovirals, protease inhibitors (PI)

Indications

HIV infection

The combination of darunavir / ritonavir is the preferred boosted protease inhibitor option for ART if a protease inhibitor is needed.

Combinations of atazanavir + ritonavir or lopinavir + ritonavir can be used as alternatives if darunavir / ritonavir cannot be used.

Instructions for use

DRV eq. 400mg base / r 50mg, tablet is first choice over LPV 100mg / r 25mg and LPV 200mg / r 50mg, tablets.

The LPV 40mg / r 10mg granules in sachet are intended for paediatric use:

  • pour the granules into a small amount of breast milk, water or soft foods
  • administer immediately (within a maximum of 2 hours after preparation).

Storage

Below 25ºC - Protect from sunlight - Protect from humidity